Basilea appoints Chief Commercial Officer - Seite 2

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options. Basilea's pipeline includes the antibiotic Zevtera^®/Mabelio^® (ceftobiprole medocaril) and the antifungal isavuconazole.

Zevtera/Mabelio is a bactericidal broad-spectrum intravenous antibiotic from the cephalosporin class, covering Gram-positive and Gram-negative pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas spp., which are frequent causes of hospital-acquired pneumonia.¹ It is approved for the treatment of adults with hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP) in certain European countries² and is currently under regulatory review in Switzerland.

Isavuconazole (drug substance: isavuconazonium sulfate) is an investigational once-daily intravenous and oral broad-spectrum antifungal for the potential treatment of life-threatening invasive fungal infections which predominantly occur in immunocompromised patients such as cancer patients undergoing chemotherapy. It has EU and U.S. orphan drug status for the treatment of invasive aspergillosis and mucormycosis. In the U.S., isavuconazole was granted FDA fast-track status and designated a Qualified Infectious Disease Product (QIDP) for invasive aspergillosis, mucormycosis and candidiasis under the U.S. GAIN Act. In July 2014, Basilea submitted a European Marketing Authorization Application (MAA) and its co-development partner Astellas Pharma Inc. submitted a U.S. New Drug Application (NDA) seeking isavuconazole approval for the treatment of invasive aspergillosis and mucormycosis. Basilea holds full rights to isavuconazole in markets outside of the U.S. and Canada where Astellas is the license holder.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.